Clinical Liver Disease (CLD), an official digital learning resource of The American Association for the Study of Liver Diseases is an interactive, up-to-date source of education, designed for physicians and healthcare providers caring for the patient with liver disease. CLD provides current and clinically relevant information through educational interventions every two months.
Use of quantitative hepatitis B surface antigen with hepatitis B virus DNA in clinical practice - Grace Lai-Hung Wong and Henry Lik-Yuen Chan – Article Reading07/07/2013 Duración: 06min
Quantitative Hepatitis B Surface Antigen provides information concerning disease activity over and above an estimation of viral replication. It is an indispensable tool in the clinical assessment and management of chronic hepatitis B viral infection. Drs. Wong and Chan highlight what the clinician needs to know.
Solid organ transplantation and hepatitis B virus - Federico Villamil and Fernando Cairo – Article Reading.07/07/2013 Duración: 06min
Drs. Villamil and Cairo review the best available evidence on managing the HBV patient who has received a solid organ transplantation. For liver transplant patients, the authors address whether there is a role for hepatitis B immunoglobulin, whether antiviral monotherapy sufficient, and how best to manage liver transplantations from antibody to hepatitis B core antigen (anti-HBc) positive donors. In the kidney transplant patient, Drs. Villamil and Cairo discuss kidney transplant in HBsAg-positive patients, as well as kidney transplants from anti-HBc positive donors.
Hepatitis B virus treatment: Which patients should be treated with nucleos(t)ide analogue? - Mauro Viganò and Pietro Lampertico – Article Reading07/07/2013 Duración: 06min
Drs. Vigano and Lampertico weigh in on the nucleos(t)ide analogues (NAs)-pegylated interferon (PEG-IFN) debate, addressing first line therapy selection, monitoring of the patient treated with NAs, and when if ever it is appropriate to stop treatment.
Hepatitis B virus in pregnancy - Tram T. Tran – Article Reading07/07/2013 Duración: 06min
Tram Tran, MD, an Associate Professor of Medicine from Cedars Sinai Medical Center and a CLD author, discusses HBV treatment in a woman of reproductive age. Dr. Tran addresses HBV transmission risk in pregnancy, antiviral therapy in women of childbearing age and treatment in the third trimester, as well as introducing treatment algorithms for the management of HBV in women planning a pregnancy, with an unexpected pregnancy, and during pregnancy.
Hepatitis B virus treatment: Management of antiviral drug resistance - Michele M. Tana and Marc G. Ghany – Article Reading07/07/2013 Duración: 06min
Although effective therapies for chronic Hepatitis B are available, antiviral drug resistance represents a serious potential complication. With very few new drugs in the development pipeline, providers must make every effort to prevent resistance by following clear indications for therapy, counseling patients repeatedly on adherence, and monitoring closely for the development of virologic breakthrough. Drs. Tana and Ghany explain.
Hepatitis B virus treatment: Which patients require immediate treatment - Robert P. Perrillo – Article Reading07/07/2013 Duración: 06min
In some clinical situations, Hepatitis B requires immediate treatment. Dr. Perrillo reviews the characteristics of patients who may need prompt or even urgent care..
Hepatitis B virus treatment: Which patients can have treatment deferred? - George V. Papatheodoridis – Article Reading07/07/2013 Duración: 06min
Treatment can be deferred in chronic HBV patients with inactive or mild liver disease without risk of liver disease progression, while patients with active or advanced liver disease should be treated. Dr. Papatheodoridis reviews approaches to classifying patients and how to determine the most appropriate treatment plans.
Viral hepatitis B coinfection with human immunodeficiency virus, hepatitis D virus, or hepatitis C virus - Tuyet A. T. Nguyen and Richard K. Sterling – Article Reading07/07/2013 Duración: 06min
Patients with chronic Hepatitis B may also have concomitant infection with hepatitis delta virus (HDV), human immuno-deficiency virus (HIV), and/or hepatitis C virus (HCV). Because of the potential for coinfection, patients who are diagnosed with HBV therefore should be tested for their presence. Drs. Nguyen and Sterling review the essentials of diagnosis and management of the coinfected patient.
Hepatitis B virus infection in children - Maureen M. Jonas – Article Reading07/07/2013 Duración: 06min
Most cases of Hepatitis B that cause long-term morbidity and mortality had their origin during the patient’s childhood, according to Maureen Jonas, MD from Boston Children’s Hospital and Harvard Medical School. Listen to the podcast to better understand the risks of and management strategies for HBV in children, and to review monitoring and treatment algorithms for children with HBV..
Hepatopathology of hepatitis B - Zachary D. Goodman – Article Reading07/07/2013 Duración: 06min
This liver biopsy from a patient with markedly active chronic hepatitis B has considerable chronic portal inflammation, predominantly lymphocytes, which migrate out of the portal tract to surround and destroy adjacent hepatocytes. Review this and other histologic features associated with the active immune response to HBV in Dr. Goodman’s review of hepatopathology of HBV.
Evaluation of the patient with chronic hepatitis B - Robert J. Fontana – Article Reading07/07/2013 Duración: 06min
All newly diagnosed chronic Hepatitis B patients should undergo a complete history, physical assessment, and laboratory assessment in an effort to assess the severity of liver disease and potential need for antiviral therapy. Watch, read, or listen to Dr. Fontana describe recommended testing and markers of HBV replication, as well as other approaches to evaluating the patient.
HBV treatment in a patient who will be receiving immunosuppressive therapy - Jordan J. Feld – Article Reading07/07/2013 Duración: 06min
: HBV is noncytopathic, with hepatic injury occurring as a result of the host immune response against the virus. As a result, the interaction between HBV and the immune system is critical in determining the outcome of infection. Dr. Feld reviews reverse seroconversion, HBV reactivation, prevention, screening, and management strategies.
Hepatitis B virus treatment: Which patients should be treated with interferon?07/07/2013 Duración: 06min
Both nucleos(t)ide analogues (NAs) and pegylated interferon (PEG-IFN) have proven to be effective, but current guidelines are lacking clear recommendations as to which treatment strategy should be used as first-line therapy. The authors review the best available evidence regarding which patients should be treated with interferon.
Drug resistance: Prevalence and clinical implications during the treatment of chronic hepatitis C infection, Jean-Michel Pawlotsky - Article Reading21/08/2012 Duración: 09min
The recent development of direct-acting antiviral (DAA) molecules that are active on hepatitis C virus (HCV) has raised the concern that resistance may undermine therapy based on DAAs.
HCV infection on-treatment viral kinetics: Do they still have a role? Jordan J. Feld - Article Reading21/08/2012 Duración: 14min
As soon as it was recognized that interferon-based therapy could lead to long-term viral eradication or a sustained virological response (SVR), the search was on for predictors of responses to therapy. With low response rates and the need for prolonged, costly, and difficult therapy, the primary goal was to identify patients who were unlikely to respond to treatment so that fruitless therapy could be avoided.
Treatment options for anti-HCV treatment-experienced patients, Peter Ferenci - Article Reading21/08/2012 Duración: 08min
Treatment failure with pegylated interferon (PEG-IFN)/ribavirin (RBV) dual therapy can be due to either the persistence of hepatitis C virus (HCV) RNA throughout treatment (nonresponse) or the reappearance of the virus after the end of treatment.
Issues in selecting HCV-infected candidates for anti-viral treatment, Anna S. Lok - Article Reading21/08/2012 Duración: 07min
The recent approval of two protease inhibitors (telaprevir and boceprevir) and the resultant increase in the sustained virological response (SVR) rate when either of these drugs is added to pegylated interferon (PEG-IFN) and ribavirin (RBV) have led to a flurry of patients with hepatitis C virus (HCV) infection seeking treatment.